MA31036B1 - Inhibiteurs non nucleosidiques de la transcriptase inverse - Google Patents

Inhibiteurs non nucleosidiques de la transcriptase inverse

Info

Publication number
MA31036B1
MA31036B1 MA32059A MA32059A MA31036B1 MA 31036 B1 MA31036 B1 MA 31036B1 MA 32059 A MA32059 A MA 32059A MA 32059 A MA32059 A MA 32059A MA 31036 B1 MA31036 B1 MA 31036B1
Authority
MA
Morocco
Prior art keywords
compounds
reverse transcriptase
hiv
prophylaxis
formula
Prior art date
Application number
MA32059A
Other languages
English (en)
Inventor
Neville J Anthony
Robert Gomez
Samson M Jolly
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA31036B1 publication Critical patent/MA31036B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE I: (I), QUI CONSISTENT EN DES INHIBITEURS DE LA TRANSCRIPTASE INVERSE DU VIH, Q, R2, R3, R6, T1, T2, ET T3 ÉTANT DÉFINIS DANS LE PRÉSENT DOCUMENT. LES COMPOSÉS DE FORMULE I, ET LES SELS ET PROMÉDICAMENTS DE CEUX-CI ACCEPTABLES SUR LE PLAN PHARMACEUTIQUE, SONT UTILES DANS L'INHIBITION DE LA TRANSCRIPTASE INVERSE DU VIH, DANS LA PROPHYLAXIE ET LE TRAITEMENT D'INFECTION PAR LE VIH ET DANS LA PROPHYLAXIE, LE RETARDEMENT DE L'APPARITION OU DE LA PROGRESSION, ET LE TRAITEMENT DU SIDA. LES COMPOSÉS ET LEURS SELS PEUVENT ÊTRE UTILISÉS COMME INGRÉDIENTS DANS DES COMPOSITIONS PHARMACEUTIQUES, FACULTATIVEMENT COMBINÉS À D'AUTRES ANTIVIRAUX, IMMUNOMODULATEURS, ANTIBIOTIQUES OU VACCINS.
MA32059A 2006-12-13 2009-06-30 Inhibiteurs non nucleosidiques de la transcriptase inverse MA31036B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87462906P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
MA31036B1 true MA31036B1 (fr) 2009-12-01

Family

ID=39277099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32059A MA31036B1 (fr) 2006-12-13 2009-06-30 Inhibiteurs non nucleosidiques de la transcriptase inverse

Country Status (29)

Country Link
US (2) US7781454B2 (fr)
EP (1) EP2121638B1 (fr)
JP (1) JP5123949B2 (fr)
KR (1) KR20090087481A (fr)
CN (1) CN101558050A (fr)
AR (1) AR064199A1 (fr)
AU (1) AU2007334598B2 (fr)
BR (1) BRPI0720196A2 (fr)
CA (1) CA2673093A1 (fr)
CL (1) CL2007003594A1 (fr)
CR (1) CR10843A (fr)
DO (1) DOP2009000138A (fr)
EA (1) EA200970572A1 (fr)
EC (1) ECSP099373A (fr)
GE (1) GEP20115320B (fr)
GT (1) GT200900158A (fr)
HN (1) HN2009001160A (fr)
IL (1) IL199103A0 (fr)
MA (1) MA31036B1 (fr)
MX (1) MX2009006285A (fr)
NI (1) NI200900103A (fr)
NO (1) NO20092636L (fr)
NZ (1) NZ577637A (fr)
PE (1) PE20081448A1 (fr)
SV (1) SV2009003294A (fr)
TN (1) TN2009000243A1 (fr)
TW (1) TW200831085A (fr)
WO (2) WO2008076225A2 (fr)
ZA (1) ZA200903395B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5433579B2 (ja) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
RS51660B (en) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP5269087B2 (ja) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
WO2009067166A2 (fr) * 2007-11-20 2009-05-28 Merck & Co., Inc. Inhibiteurs non-nucléosidiques de la transcriptase inverse
WO2009117278A2 (fr) * 2008-03-20 2009-09-24 Merck & Co., Inc. Procédés de préparation d'éthers de biaryle substitués par un (amino-pyrazolopyridinyl)méthoxy
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
GEP20156368B (en) 2010-03-30 2015-09-25 Merck Canada Inc Non-nucleoside reverse transcriptase inhibitors
WO2012062759A1 (fr) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2814996C (fr) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. Derives de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
WO2012078416A2 (fr) * 2010-12-06 2012-06-14 Rfs Pharma, Llc Promédicaments monophosphatés de dapd et leurs analogues
EP2744481A4 (fr) * 2011-08-16 2015-07-01 Merck Sharp & Dohme Utilisation de matrice inorganique et de combinaisons de polymères organiques pour la préparation de dispersions amorphes stables
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
PT2861566T (pt) 2012-06-13 2017-02-08 Hoffmann La Roche Novos diazaspirocicloalcanos e azaspirocicloalcanos
UA116547C2 (uk) 2012-09-25 2018-04-10 Ф. Хоффманн-Ля Рош Аг Біциклічні похідні
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN103848826A (zh) * 2012-11-30 2014-06-11 南京大学 一类含苯并三氮唑结构的1,3,4-恶二唑类衍生物的制法与用途
CN103848827A (zh) * 2012-11-30 2014-06-11 南京大学 一种含苯并三氮唑类衍生物在抗癌药物中的应用
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
BR112016022722B8 (pt) 2014-04-01 2023-11-21 Merck Sharp & Dohme Composto, composição farmacêutica que o comprende e uso do mesmo
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
CA2983782A1 (fr) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Composes bicycliques utilises en tant qu'inhibiteurs d'atx
WO2017050791A1 (fr) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs doubles d'atx/ca
CN107922412B (zh) 2015-09-24 2021-02-23 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
CA2984585A1 (fr) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Nouveaux composes bicycliques utilises en tant qu'inhibiteurs doubles d'atx/ca
CN105906482B (zh) * 2016-05-19 2019-02-12 江苏优嘉植物保护有限公司 一种利用2,5-二氯酚醚制备2,5-二氯苯酚的方法
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
CA3143436A1 (fr) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugues de composes azotes heteroaromatiques donneurs de paires d'electrons p
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
SU1049487A1 (ru) * 1982-06-24 1983-10-23 Новокузнецкий научно-исследовательский химико-фармацевтический институт Способ получени @ -аминокетонов бензимидазольного р да
US5358950A (en) * 1991-07-05 1994-10-25 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0963371B1 (fr) * 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Benzimidazoles substitues comme inhibiteurs non nucleosidiques de transcriptase inverse
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
US7365090B2 (en) 2002-08-07 2008-04-29 Idenix Pharmaceuticals, Inc. Substituted phenylindoles for the treatment of HIV
JP2006511486A (ja) 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Crth2拮抗剤としてのテトラヒドロキノリン誘導体
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
WO2004078116A2 (fr) 2003-03-03 2004-09-16 Array Biopharma, Inc. Inhibiteurs de la p 38 et leurs procedes d'utilisation
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
WO2005115147A2 (fr) 2004-05-18 2005-12-08 Merck & Co., Inc. Inhibiteurs de la transcriptase inverse du vih
EP1753730A1 (fr) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
CN1993332B (zh) 2004-07-27 2011-04-06 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
WO2006102112A2 (fr) * 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Recepteur 1 de prokineticine
CA2612592A1 (fr) 2005-06-28 2007-01-04 Merck & Co., Inc. Inhibiteurs non nucleosidiques de la transcriptase inverse
US20100222322A1 (en) 2005-06-28 2010-09-02 Merck & Co., Inc. Non-Nucleoside Reverse Transcriptase Inhibitors
EP1898927A2 (fr) 2005-06-28 2008-03-19 Merck & Co., Inc. Inhibiteurs non nucleosidiques de la transcriptase inverse
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ATE503744T1 (de) 2006-08-16 2011-04-15 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
CN101535298A (zh) * 2006-11-16 2009-09-16 弗·哈夫曼-拉罗切有限公司 取代的4-咪唑类化合物
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
DOP2009000138A (es) 2009-11-15
US20100286192A1 (en) 2010-11-11
GEP20115320B (en) 2011-10-25
PE20081448A1 (es) 2008-10-19
AR064199A1 (es) 2009-03-18
AU2007334598B2 (en) 2013-01-17
TW200831085A (en) 2008-08-01
NI200900103A (es) 2010-01-26
US20080275097A1 (en) 2008-11-06
AU2007334598A1 (en) 2008-06-26
WO2008076223A1 (fr) 2008-06-26
US7781454B2 (en) 2010-08-24
NO20092636L (no) 2009-09-08
EA200970572A1 (ru) 2009-12-30
EP2121638B1 (fr) 2016-05-25
JP5123949B2 (ja) 2013-01-23
ECSP099373A (es) 2009-07-31
KR20090087481A (ko) 2009-08-17
CL2007003594A1 (es) 2008-05-30
JP2010510989A (ja) 2010-04-08
CN101558050A (zh) 2009-10-14
GT200900158A (es) 2009-10-14
CR10843A (es) 2009-08-12
HN2009001160A (es) 2011-10-11
ZA200903395B (en) 2010-05-26
NZ577637A (en) 2011-05-27
IL199103A0 (en) 2010-03-28
TN2009000243A1 (en) 2010-10-18
CA2673093A1 (fr) 2008-06-26
SV2009003294A (es) 2009-11-09
BRPI0720196A2 (pt) 2013-12-31
EP2121638A2 (fr) 2009-11-25
WO2008076225A2 (fr) 2008-06-26
WO2008076225A3 (fr) 2008-08-07
MX2009006285A (es) 2009-06-23

Similar Documents

Publication Publication Date Title
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA29745B1 (fr) Inhibiteurs de la transcriptase inverse du vih
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
MA34002B1 (fr) Thérapie antivirale
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA31754B1 (fr) Cis-imidazolines chirales
EA200601654A1 (ru) Ингибиторы интегразы вич
MA44674A (fr) Inhibiteurs de bromodomaine
DE60218511D1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
GEP20053619B (en) Pyrazole Derivatives for Treating HIV
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
TNSN07022A1 (fr) Derives de pyridine
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA30014B1 (fr) Derives spirocycliques
ATE517899T1 (de) Hiv-integrasehemmer
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
DE60322919D1 (de) 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
EA200900552A1 (ru) Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
ATE386741T1 (de) Pyrazolamide zur behandlung von hiv-infektionen